THE EFFECTIVENESS OF ZINC AND RISEDRONATE ON BONE TURNOVER IN RAT MODEL OF OSTEOPOROSIS ASSESSED WITH THE EXPRESSION OF β-CROSSLAPS
Downloads
Background: Osteoporosis prevalence in Indonesia is high. Risedronate commonly used for treating the osteoporosis. Unfortunately, long term therapy can cause hazardous adverse effect to the patient. Previous research in rat model osteoporosis, Zinc have a potential effect to prevent and rebuild bone structure with osteoblast stimulation in bone formation and osteoclast activity inhibition in bone resorption by increasing Osteoprotegerin production, that inhibit bond between RANKL and RANK.
Purpose: To determine the effectiveness of Zink and Risedronate on bone turnover in osteoporotic model rats assessed the β-CrossLaps expression.
Methods: This research is conducted as experimental comparative method used 25 female Galur Wistar rat that divided into Non-ovariectomy and Ovariectomy group to induce osteoporosis. The treatment is divided into Zinc-Risedronate, and Zinc, or Risedronate only. One Way Anova and Independent T-test was used to analyzed the significant difference between groups.
Result: One Way Anova statistic test forβ-CrossLaps expression value in the 3rd Taken blood sample showed that p is less than 0.05 (p<0.05), which indicated that are significant difference in the mean between variable at 3rd Taken blood sample in all group. Meanwhile, Independent T-test was used to compare β-CrossLaps expression in 3rd taken blood sample between Ovari and Ovari+Zinc, Ovari and Ovari+Zinc+Rise showed p is less than 0.05 (p<0.05), which indicated that there are significant difference in the mean between variable 2 groups.
Conclusion: Zinc-Risedronate administration will decrease bone turnover and β-CrossLaps expression more than Zinc or Risedronate only in rat model osteoporosis.Noor Z, Kania N, Setiawan B. Tibia Bone Properties at Different Time Course of Ovariectomized Rats. Journal of Diabetes & Metabolic Disorder. 2014;13(91): 1-7
Mithal A, Ebeling P. The Asia-Pacific Regional Audit. Epidemiology, cost and burden of Osteoporosis in 2013. International Osteoporosis Foundation. 2015; 56-60
Gurban CV, Mederle O. The OPG/RANKL System and Zinc Ions are Promoters of Bone Remodeling by Osteoblast Proliferation in Postmenopausal Osteoporosis. Department of Biochemistry, University of Medicine and Pharmacy, Timisoara. Rom J Morphol Embryol. 2011, 52(3 Suppl):1113–1119
Watts NB, Camacho PM, Harris ST, Kleerekoper M. American Association of Clinical Endocrinologist Medical Guidelines for Clinical Practice For The Diagnosis and Treatment of Postmenopausal Osteoporosis. AACE Guidelines. Endocrine Practice Vol 16 (Suppl 3). 2010; 5-14
Nuti R. Updates on Mechanism of Action and Clincal Efficacy on Risedronate in Osteoporosis. Medical and Surgical Science and Neuroscience Department. University of Siena. Clinical Cases in Mineral and Bone Metabolism. 2014; 11(3): 208-214
Lolascon G, Sirico F, Ferrante A. Risedronate's Efficacy. From Randomized Clinical Trial to Real Clinical Practice. Department of Orthopaedics and Rehabilitation Medicine. University of Naples. Clinical Cases in Mineral and Bone Metabolism. 2010; 7(1): 19-22
Yamaguchi M. Osteoporosis Treatment with New Osteogenic Factors. Department of Hematology and Medical Oncology, Emory University School of Medicine. J Mol Genet Med. 2013; 7: 2
Yamaguchi M. New Development in Osteoporosis Treatment. The Synergistical Osteogenic Effects with Vitamin D3, Menaquinone-7, Genistein and Zinc. Vitam Miner 2013; S6-e001
Puspitawati I, Windarwati, Sukorini U, Herowati P, Prabowo A. Kadar CTX Perempuan Osteoporosis Lebih Tinggi Daripada Perempuan Normal dan Osteopenia. Indonesian Jurnal of Clinical Pathology and Medical Laboratory. 2013; Vol.19,No. 3: 161-166
Lee J, Vasikaran S. Current Recommendations for Laboratory Testing and Use of Bone Turnover Markers in Management of Osteoporosis. Department of Core Clinical Pathology and Biochemistry. PathWest-Royal Perth Hospital. Ann Lab Med. 2012; 2: 105-112
Arslan M, Cogendez E, Eken M, Arioglu PF, Eren S. Serum Beta Crosslaps as a Predictor for Osteoporosis in Postmenopausal Women. Zeynep Kamil Education and Research Hospital, Obstetric and Gynecology Department. Istanbul, Turkey. 2015; 78 (2): 36-40
Govindarajan P, Khassawna T, Kampschulte M. Implication of Combined Ovariectomy and Glucocorticoid (dexamethasone) Treatment on Mineral, Microarchitectural, Biomechanical and Matrix Properties of rat bone. Laboratory of Experimental Trauma Surgery. Int. J. Exp. Path. 2013; 94: 387–398
Yao W, Cheng Z, Pham A. Glucocorticoid-Induced Bone Loss in Mice Can Be Reversed by the Actions of Parathyroid Hormone and Risedronate on Different Pathways for Bone Formation and Mineralization. Arthritis and Rheumatism. American Collage of Rheumatology. 2008; Vol.58,No.11: 3485–3497
Lelovas P, Xanthos T, Thoma SE, Lyritis GP. The Laboratory Rat as an Animal Model for Osteoporosis Research. American Association for Laboratory Animal Science. 2008; Vol 58,No.5: 424-430.
Ren H, Liang D, Shen G, Yao Z, Jiang X. Effects of Combined Ovariectomy with Dexamethasone on Rat Lumbar Vertebrae. Menopause: The Journal of The North American Society. 2015; Vol.23.No.4: 441-450.
Abbexa Ltd. Rat beta Crosslaps (bCTx) ELISA Kit. Cambridge Science Park. 2017. Cat. No. abx256110
Khajuria DK, Disha C, Vasireddi R, Mahapatra R. Risedronate/Zinc-Hydroxyapatite Base Nanomedicine for Osteoporosis. Material Science and Engineering. 2016;Vol.63: 78-87.
- The author acknowledges that the copyright of the article is transferred to the Journal of Orthopaedi and Traumatology Surabaya (JOINTS), whilst the author retains the moral right to the publication.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License (CC BY-NC-SA).
- All published manuscripts, whether in print or electronic form, are open access for educational, research, library purposes, and non-commercial uses. In addition to the aims mentioned above, the editorial board is not liable for any potential violations of copyright laws.
- The form to submit the manuscript's authenticity and copyright statement can be downloaded here.
Journal of Orthopaedi and Traumatology Surabaya (JOINTS) is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License.
Journal Orthopaedi and Traumatology Surabaya (JOINTS) (